New concepts in hypertrophic cardiomyopathies, part II.
Roberts
R
R
Section of Cardiology, Baylor College of Medicine, Houston, Tex, and The Royal Brompton Hospital, London, UK. rroberts@bcm.tmc.edu
Sigwart
U
U
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D006348:Cardiac Surgical Procedures; D002312:Cardiomyopathy, Hypertrophic / Q000503:physiopathology / Q000628:therapy*; D017147:Defibrillators, Implantable; D004195:Disease Models, Animal; D000431:Ethanol / Q000008:administration & dosage; D020022:Genetic Predisposition to Disease; D006346:Heart Septum / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007269:Injections, Intra-Arterial
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D000431:Ethanol